Pharmacological Interventions for Glucocorticoid-Induced Osteoporosis: An Umbrella Review

Overview

Journal Horm Metab Res

Specialty Endocrinology

Date 2023 Jun 19

PMID 37336498

Authors

Haodong Liang

Jinlong Zhao

Tianzhao Tian

Affiliations

Soon will be listed here.

Abstract

There is still a lack of high-quality evidence-based studies on the efficacy of drug treatment for glucocorticoid-induced osteoporosis (GIOP). The purpose of this umbrella review is to comprehensively evaluate the existing evidence to determine the efficacy and safety of pharmacological interventions for GIOP. We searched PubMed, Embase, and the Cochrane Library for systematic reviews and/or meta-analyses (SRs) of randomized controlled trials (RCTs) aimed at evaluating drug therapy for GIOP. Both the methodological quality and the strength of recommendation of the endpoints included in the SRs were evaluated by using the AMSTAR-2 tool and GRADE system, respectively. Six SRs involving 7225 GIOP patients in 59 RCTs were included in this umbrella review. The results of the methodological quality evaluation showed that 2 high-quality, 2 low-quality and 2 critically low-quality SRs were included. The GRADE evaluation results showed that the quality of evidence and the strength of recommendation of 46 outcome indicators were evaluated in the umbrella review; there were 3 with high-level evidence, 20 with moderate-level evidence, 15 with low-level evidence, and 8 with very low-level evidence. Moderate- to high-level evidence suggests that teriparatide, bisphosphonates, and denosumab can improve the bone mineral density in patients with GIOP. The findings of this umbrella review can enable patients and clinical healthcare professionals to choose the best drug prescription.

References

Finkelstein J, Hayes A, Hunzelman J, Wyland J, Lee H, Neer R . The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349(13):1216-26. DOI: 10.1056/NEJMoa035725. View

Wang J, Li H . Treatment of Glucocorticoid-Induced Osteoporosis with Bisphosphonates Alone, Vitamin D Alone or a Combination Treatment in Eastern Asians: A Meta-Analysis. Curr Pharm Des. 2019; 25(14):1653-1662. PMC: 7046985. DOI: 10.2174/1381612825666190619125426. View

Allen C, Yeung J, Vandermeer B, Homik J . Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016; 10:CD001347. PMC: 6461188. DOI: 10.1002/14651858.CD001347.pub2. View

Chotiyarnwong P, McCloskey E . Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020; 16(8):437-447. DOI: 10.1038/s41574-020-0341-0. View

Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. PMC: 5833365. DOI: 10.1136/bmj.j4008. View

Compston J, McClung M, Leslie W . Osteoporosis. Lancet. 2019; 393(10169):364-376. DOI: 10.1016/S0140-6736(18)32112-3. View

Zeng Y, Huang C, Duan D, Lou A, Guo Y, Xiao T . Injectable temperature-sensitive hydrogel system incorporating deferoxamine-loaded microspheres promotes H-type blood vessel-related bone repair of a critical size femoral defect. Acta Biomater. 2022; 153:108-123. DOI: 10.1016/j.actbio.2022.09.018. View

Weinstein R . Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365(1):62-70. DOI: 10.1056/NEJMcp1012926. View

Wang T, Liu X, He C . Glucocorticoid-induced autophagy and apoptosis in bone. Apoptosis. 2020; 25(3-4):157-168. DOI: 10.1007/s10495-020-01599-0. View

10.

de Vries F, Bracke M, Leufkens H, Lammers J, Cooper C, van Staa T . Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2006; 56(1):208-14. DOI: 10.1002/art.22294. View

11.

Kim K, Min Y, Koh J, Chung Y, Kim K, Byun D . Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial. Yonsei Med J. 2014; 55(3):715-24. PMC: 3990072. DOI: 10.3349/ymj.2014.55.3.715. View

12.

Homik J, Suarez-Almazor M, Shea B, Cranney A, Wells G, Tugwell P . Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD000952. PMC: 7046131. DOI: 10.1002/14651858.CD000952. View

13.

Banuelos J, Shin S, Cao Y, Bochner B, Morales-Nebreda L, Budinger G . BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis. Allergy. 2016; 71(5):640-50. PMC: 4844778. DOI: 10.1111/all.12840. View

14.

Valenti M, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S . The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010; 12(4):R163. PMC: 2945066. DOI: 10.1186/ar3122. View

15.

Messina O, Vidal L, Wilman M, Bultink I, Raterman H, Lems W . Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res. 2021; 33(4):793-804. DOI: 10.1007/s40520-021-01823-0. View

16.

Bouxsein M, Chen P, Glass E, Kallmes D, Delmas P, Mitlak B . Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am. 2009; 91(6):1329-38. DOI: 10.2106/JBJS.H.01030. View

17.

Liu Z, Zhang M, Zong Y, Zhang D, Shen Z, Guan X . The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials. PLoS One. 2022; 17(5):e0267706. PMC: 9154179. DOI: 10.1371/journal.pone.0267706. View

18.

Oura P, Karppinen J, Niinimaki J, Junno J . Sex estimation from dimensions of the fourth lumbar vertebra in Northern Finns of 20, 30, and 46 years of age. Forensic Sci Int. 2018; 290:350.e1-350.e6. DOI: 10.1016/j.forsciint.2018.07.011. View

19.

Fardet L, Petersen I, Nazareth I . Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore). 2015; 94(15):e647. PMC: 4602514. DOI: 10.1097/MD.0000000000000647. View

20.

Buckley L, Guyatt G, Fink H, Cannon M, Grossman J, Hansen K . 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017; 69(8):1095-1110. DOI: 10.1002/acr.23279. View